Trial Type: Brain Tumors

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations. Types: Subprotocol A: BRAF Fusions in Primary CNS and Other Solid Tumors, Subprotocol B: BRAF V600 Mutated Recurrent Primary CNS Tumors, Subprotocol C: Rare BRAF V600 Mutated Solid Tumors (non-CNS), Subprotocol D: Selected BRAF Altered Solid Tumors

Phase 1b study to evaluate eflornithine plus temozolomide in patients with newly diagnosed glioblastoma

Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41).